Nalaganje...
Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now...
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4069138/ https://ncbi.nlm.nih.gov/pubmed/24971016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S40527 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|